Titanocene dichloride, which is an active antitumor agent against solid but not blood-borne tumors, suppresses angiogenesis and inhibits biosynthesis of collagenous proteins in the in vivo system of the chorioallantoic membrane of the chick embryo. The agent does not affect total protein biosynthesis in the same system. At non-toxic dose regimens titanocene dichloride retards the growth of Walker 256 carcinosarcoma transplants in rats and reduces the number of seeded implants in the mesenteric bed. At concentrations which suppress angiogenesis and inhibit biosynthesis of collagenous proteins, the agent does not affect the viability of Walker 256 carcinosarcoma cells, or the attachment and proliferation of human A549 lung adenocarcinoma or human umbilical vein endothelial cells in culture. It appears that the antitumor activity of titanocene dichloride may be attributed, at least in part, to its ability to suppress angiogenesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0014-2999(94)90408-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Choosing between Ti(II) and Ti(III): selective reduction of titanocene dichloride by elemental lanthanides.
Dalton Trans
September 2024
Université de Reims Champagne Ardenne, CNRS UMR 7312, ICMR, URCATech, 51100 Reims, France.
The reduction of titanocene dichloride CpTiCl with lanthanide metals has led to the discovery of a surprising lanthanide effect: while with most lanthanides, a divalent [CpTi] equivalent was obtained, the use of samarium or ytterbium only led to the reduction to trivalent [CpTiCl]-type complexes, including the structurally characterized heterobimetallic complex [CpTi(μ-Cl)SmCl(THF)]. These results were corroborated by reactivity studies (alkyne coupling and radical reactions), EPR spectroscopy and electrospray mass spectrometry, providing new insights into the reduction chemistry of lanthanide metals.
View Article and Find Full Text PDFA Comprehensive Review on the Development of Titanium Complexes as Cytotoxic Agents.
Curr Top Med Chem
October 2024
Department of Chemistry, National Institute of Technology, Hamirpur, Himachal Pradesh, 177005, India.
After the discovery of cis-platin, the first metal-based anticancer drugs, budotitane, and titanocene dichloride entered clinical trials. These two classes of complexes were effective against those cell lines that are resistant to cis-platin and other platinum-based drugs. However, the main limitation of these complexes is their low hydrolytic stability.
View Article and Find Full Text PDFAnti-tumoral Titanium Complexes Stabilized with Phenolato Ligands and Structure-Activity Relationship.
Curr Top Med Chem
August 2023
Fachbereich Chemie and Konstanz Research School Chemical Biology, Universität Konstanz, Universitätsstr, 10, D-78457, Konstanz, Germany.
Titanocene dichloride and budotitane have opened a new chapter in medicinal chemistry of titanium complexes being novel non-platinum antitumor metallic agents. Numerous efforts have led to the discovery of the diamino -phenolato titanium complexes. Among which, the [ONNO] and [ONON] type ligands namely Salan, Salen and Salalen coordinated titanium alkoxyl complexes have demonstrated significantly enhanced aqueous stability, their and antitumor efficacy, mechanism of action, structure-activity relationships and combined tumor therapy have been intensively investigated.
View Article and Find Full Text PDFNew Titanocene (IV) Dicarboxylates with Potential Cytotoxicity: Synthesis, Structure, Stability and Electrochemistry.
Int J Mol Sci
February 2023
Chemistry Department, Lomonosov Moscow State University, 1/3 Leninskie Gory, 119991 Moscow, Russia.
The search for new anticancer drugs based on biogenic metals, which have weaker side effects compared to platinum-based drugs, remains an urgent task in medicinal chemistry. Titanocene dichloride, a coordination compound of fully biocompatible titanium, has failed in pre-clinical trials but continues to attract the attention of researchers as a structural framework for the development of new cytotoxic compounds. In this study, a series of titanocene (IV) carboxylate complexes, both new and those known from the literature, was synthesized, and their structures were confirmed by a complex of physicochemical methods and X-ray diffraction analysis (including one previously unknown structure based on perfluorinated benzoic acid).
View Article and Find Full Text PDFAdvances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects.
Pharmacol Ther
January 2023
Department of Chemistry, Aligarh Muslim University, Aligarh 202002, UP, India. Electronic address:
Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!